Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:27:46 EDT Fri 17 Apr 2026
Enter Symbol
or Name
USA
CA



Q:SGMO - SANGAMO THERAPEUTICS INC - https://www.sangamo.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SGMO - Q0.10.2424·0.555.00.262-0.008-3.03,126.76834,7460.2759  0.284  0.2620.84  0.206119:48:50Mar 3015 min RT 2¢

Recent Trades - Last 10 of 4746
Time ETExPriceChangeVolume
19:48:50Q0.2699-0.0001355
19:48:30Q0.2699-0.00018
19:08:14Q0.27 50
19:05:04Q0.27020.000250
18:59:17Q0.27020.0002300
18:57:48Q0.27020.0002200
18:51:11Q0.27030.0003500
18:48:43Q0.27030.0003370
18:38:33Q0.27520.0052578
18:32:23Q0.27520.00527,470

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-03-30 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
2026-03-19 16:03U:SGMONews ReleaseSangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
2026-03-09 08:05U:SGMONews ReleaseSangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
2026-02-03 16:05U:SGMONews ReleaseSangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium(TM) 2026
2026-02-03 09:11U:SGMONews ReleaseSangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
2025-12-18 08:05U:SGMONews ReleaseSangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
2025-12-02 08:05U:SGMONews ReleaseSangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
2025-11-21 08:05U:SGMONews ReleaseSangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
2025-11-06 08:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
2025-10-30 16:01U:SGMONews ReleaseSangamo Therapeutics Announces Third Quarter 2025 Earnings Call
2025-09-04 08:05U:SGMONews ReleaseSangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
2025-08-07 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
2025-07-31 16:05U:SGMONews ReleaseSangamo Therapeutics Announces Second Quarter 2025 Earnings Call
2025-06-24 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
2025-05-12 18:26U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
2025-05-12 18:23U:SGMONews ReleaseSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
2025-05-12 16:00U:SGMONews ReleaseSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
2025-05-06 16:35U:SGMONews ReleaseSangamo Therapeutics Announces First Quarter 2025 Earnings Call
2025-05-06 08:30U:SGMONews ReleaseSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
2025-04-28 16:31U:SGMONews ReleaseSangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)